Tasly Biopharma Pays $48 Million to Buy Out JV Partner, Transgene
publication date: Jul 10, 2018
Tasly Biopharma paid $48 million in stock to buy out its China JV partner Transgene (P: TNG), which holds China rights to two Transgene products: T601, an oncolytic virus, and T101, a therapeutic vaccine. The stock represents 2.53% of Tasly Biopharma's capital after a pre-IPO investment round, which priced at the same time as the Transgene transaction. Tasly Biopharma, the novel drug subsidiary of Tasly Pharma, has announced plans to conduct a Hong Kong IPO. The Transgene deal values the Tasly Biopharma at $1.9 billion. More details....
Stock Symbol: (SHA: 600535)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.